Positron emission tomographic imaging in drug discovery

Area of Science:

• Nuclear medicine
• Radiopharmaceutical science
• Pharmacology

Background:

• Positron emission tomography (PET) is a vital nuclear imaging technique for central nervous system (CNS) and oncological disorders.
• Drug development is a time-consuming and expensive process.
• PET imaging offers a powerful tool to streamline drug discovery and development.

Purpose of the Study:

• To review the application of PET imaging in radiopharmaceutical development.
• To explore drug development strategies employing PET imaging.
• To highlight advancements in PET imaging for oncological and cardiac drug discovery.

Main Methods:

• Review of current literature on PET imaging in drug development.
• Analysis of PET radiotracer applications for monitoring drug efficacy and safety.
• Discussion of PET's role in preclinical and clinical trial phases.

Main Results:

• PET imaging enables quantitative monitoring of receptor occupancy, drug biodistribution, and pharmacokinetic (PK) analyses.
• It validates target engagement and facilitates treatment monitoring.
• PET aids in measuring neurotransmitter concentrations, crucial for robust drug appraisal.

Conclusions:

• PET imaging significantly enhances the efficiency and reduces the cost of drug discovery and development.
• Its application is critical for evaluating novel therapeutics in CNS, oncology, and cardiology.
• Continued advancements in PET technology promise further acceleration of pharmaceutical innovation.